Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...

Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

Our manufacturing sites are state-of-the-art, powered by big data and digital. It is by producing vaccines that our mission takes on its full meaning. It is the bridge between scientific advances and ...

Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: ...

Paris, France, le 26 Septembre 2024. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q3 2024 Aide mémoire ». Résultats du troisième ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

We chase the miracles of science to improve people’s lives. But we can’t do it alone. We work closely with healthcare professionals, patient advocates, governments and industry so we can have the ...

Sanofi has strong foundations in Canada going back over a century, and operates world-leading R&D and biomanufacturing facilities in Toronto. Sanofi also operates an artificial intelligence (AI) ...